Ionis Pharmaceuticals (IONS) Scheduled to Post Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) will announce its earnings results before the market opens on Wednesday, May 4th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Ionis Pharmaceuticals has set its FY 2022 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) last posted its earnings results on Thursday, February 24th. The company reported $1.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.61. The company had revenue of $440.00 million during the quarter, compared to analysts’ expectations of $284.08 million. Ionis Pharmaceuticals had a negative net margin of 3.45% and a negative return on equity of 4.37%. Ionis Pharmaceuticals’s quarterly revenue was up 51.7% on a year-over-year basis. During the same period last year, the company posted ($2.44) earnings per share. On average, analysts expect Ionis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IONS opened at $40.12 on Wednesday. Ionis Pharmaceuticals has a fifty-two week low of $25.04 and a fifty-two week high of $44.42. The company has a debt-to-equity ratio of 1.62, a quick ratio of 9.65 and a current ratio of 9.75. The company has a fifty day moving average of $36.22 and a 200 day moving average of $33.11. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of -105.58 and a beta of 0.83.

Several equities research analysts have recently issued reports on IONS shares. Guggenheim initiated coverage on shares of Ionis Pharmaceuticals in a report on Tuesday, March 1st. They issued a “buy” rating and a $64.00 target price for the company. Bank of America downgraded shares of Ionis Pharmaceuticals from a “buy” rating to an “underperform” rating and cut their price objective for the stock from $40.00 to $30.00 in a research report on Tuesday, February 1st. Citigroup began coverage on shares of Ionis Pharmaceuticals in a research note on Monday, February 28th. They issued a “sell” rating and a $26.00 target price for the company. TheStreet upgraded shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, April 20th. Finally, StockNews.com began coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $42.28.

In related news, EVP Patrick R. O’neil sold 6,792 shares of the business’s stock in a transaction on Tuesday, April 12th. The shares were sold at an average price of $40.06, for a total value of $272,087.52. Following the completion of the transaction, the executive vice president now directly owns 34,536 shares in the company, valued at approximately $1,383,512.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 7,525 shares of company stock valued at $302,085. Company insiders own 2.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of IONS. Zullo Investment Group Inc. purchased a new stake in Ionis Pharmaceuticals in the 4th quarter worth $27,000. NEXT Financial Group Inc raised its position in Ionis Pharmaceuticals by 128.7% during the fourth quarter. NEXT Financial Group Inc now owns 2,893 shares of the company’s stock worth $88,000 after acquiring an additional 1,628 shares during the period. MML Investors Services LLC raised its position in Ionis Pharmaceuticals by 2.4% during the fourth quarter. MML Investors Services LLC now owns 25,217 shares of the company’s stock worth $767,000 after acquiring an additional 603 shares during the period. Amalgamated Bank raised its position in Ionis Pharmaceuticals by 15.4% during the fourth quarter. Amalgamated Bank now owns 29,324 shares of the company’s stock worth $892,000 after acquiring an additional 3,923 shares during the period. Finally, LPL Financial LLC raised its position in Ionis Pharmaceuticals by 6.0% during the fourth quarter. LPL Financial LLC now owns 88,666 shares of the company’s stock worth $2,698,000 after acquiring an additional 5,051 shares during the period. Hedge funds and other institutional investors own 83.97% of the company’s stock.

About Ionis Pharmaceuticals (Get Rating)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

Further Reading

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.